Cara Therapeutics Cara (NASDAQ: CARA) Receives Priority Review Of NDA For KORSUVA Cara Therapeutics, Inc. [NASDAQ: CARA] and Vifor Pharma disclosed Monday that US FDA has recognized and awarded Priority Review for the NDA for KORSUVA solution for the cure of mild-to-serious pruritus in hemodialysis sufferers.
